Administration of human leukocyte interferon to patients with subacute sclerosing panencephalitis.
Between 1979 and 1982, fifteen patients with SSPE were treated with human leukocyte interferon (HuIFN-alpha). They were administered interferon (IFN) in doses ranging from 25 x 10(6) IU to 126 x 10(6) IU by various routes in regimens that ranged for 20 days to 14 months. In 3 of the 5 cases with rapid deterioration, HuIFN-alpha did not alter the course of the disease; however, 6 cases with mild progression showed various degrees of clinical improvement during the IFN therapy. In 3 of the 4 cases in remission, HuIFN-alpha caused no significant changes in clinical courses. No severe adverse reactions were seen during IFN administration. These results suggest that HuIFN-alpha has a potentially beneficial effect on the course of SSPE.
Yoshioka
H
H
Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan.
Nishimura
O
O
Nakagawa
M
M
Ochi
M
M
Takeuchi
Y
Y
Tominaga
M
M
Hasegawa
K
K
Osamura
T
T
Goma
H
H
Sawada
T
T
D000293:Adolescent; D002648:Child; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D013036:Spasms, Infantile / Q000209:etiology; D013344:Subacute Sclerosing Panencephalitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D007370:Interferon Type I